RUTLEDGE FOUNDATION DONATES $150,000 FOR NEW SOLID TUMOR PROGRAM AT COOK CHILDREN’S MEDICAL CENTER
It has been the hope of the Rutledge Foundation since its inception, to help provide cutting edge clinical trials to solid tumor pediatric cancer patients in Fort Worth. In December, a check of $150,000 was presented to Cook Children’s Medical Center to help make a Solid Tumor Program a reality in our community. These funds have assisted in hiring the staff needed to provide genomic evaluation and participation in cutting edge, immune-based and targeted therapies like the ones that the Rutledge Foundation supports. Pediatric Solid Tumors make up 40% of all childhood cancers. The need for less toxic more curative therapies are desperately needed, and thanks to our donors, patients from North Texas will have access to new and potentially life saving therapies.
“We could not be more excited about what the new Solid Tumor Program means for sarcoma patients at Cook. Young patients will no longer have to travel to other cities for care, but will be able to stay close to their support system at home, while receiving the best new cancer therapies,”
RUTLEDGE FOUNDATION GRANTS $55,000 TO CONTINUE WORK ON LESS TOXIC NANOPARTICLE DRUG DELIVERY FOR PEDIATRIC SARCOMAS
In March, Rutledge Foundation granted $55,000 to help continue Dr. Andras Lacko’s work on a Lipoprotein Delivery System for pediatric cancers at UNT Health Science Center. This new nanoparticle delivery system hopes to minimize the short and long term side effects of otherwise toxic chemotherapies and other targeted therapies. A collaboration between UNTHSC and Texas Children’s Hospital, initiated by the Rutledge Foundation, is underway to move this exciting new drug delivery into animal studies, followed by clinical trials.
UPDATES ON RUTLEDGE SUPPORTED CLINICAL TRIALS FOR EWING SARCOMA
PHASE IIB VIGIL VACCINE MOVES FORWARD TOWARD REGISTRATION TRIAL
We are excited to report that the VIGIL Vaccine trial is advancing its reach to first time relapsed Ewing Sarcoma patients and has opened a new cohort that is used in conjunction with already accepted second line treatment. The larger, randomized trial will potentially open at the end of this year, first of next year. Multiple centers across the country are participating in this trial including: Mary Crowley Cancer Research, Cleveland Clinic, and Memorial Sloan Kettering with others opening in the coming months.
Type I Lipoplex Target for Ewing Sarcoma is Progressing
Type I Lipoplex Target for Ewing Sarcoma is moving forward, having enrolled the first 3 patients and will continue enrolling patients to evaluate this exciting, first ever drug that directly targets the Ewing cancer gene. This therapy has been funded by the Rutledge Foundation since its initial development. The Type II Lipoplex is nearing completion and once in clinical trial, will help reach 85% of Ewing patient types. Much of the funding for this novel therapy has come from our Sam Day and Lilli Curry Funds.